August 13, 2019 Novartis cast-off gives Pharming a gap-filler Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
August 30, 2018 Seeking alpha in PI3K inhibition Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.
September 02, 2016 Snippet roundup: Tecentriq gets lung cancer win, Enbrel biosimilar patent dance intensifies
